• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Jan. 7, 2015

View Archived Issues

Owl make it up to you: Minerva's preclinical PD outcome turns post-IPO gloom to cheer

Minerva Neurosciences Inc. could regain at least some of June's disappointing initial public offering (IPO) and better align its pipeline candidates, thanks to enthusiasm over preclinical data from nonhuman primates – marmosets – in Parkinson's disease (PD), results that let shares (NASDAQ:NERV) close Tuesday at $6.49, up 8.2 percent. Read More

Gilead targets NASH with $470M for Phenex Pharma drug buy

Gilead Sciences Inc. is intensifying its efforts to tackle the growing incidence of nonalcoholic steatohepatitis (NASH), buying privately held Phenex Pharmaceuticals AG's early stage farnesoid X receptor (FXR) program for up to $470 million. Read More

CAR T deals abound: Cardio3 nabs Celdara's immuno-oncology arm

LONDON – The momentum continues to build behind chimeric antigen receptor (CAR) T cells, with Cardio3 Biosciences SA acquiring Oncyte, the immuno-oncology arm of privately held Celdara Medical LLC, in the second CAR T-cell deal of the new year. Read More

Cytos 'Oncore'? $522M HBV deal offers lifeline

DUBLIN – Cytos Biotechnology AG was thrown a lifeline in the form of a new licensing deal for its Qbeta (Qb) virus-like particle (VLP) vaccine platform. Read More

Fosun to invest in biosimilars among ambitious R&D efforts

HONG KONG – The pharmaceutical arm of Chinese conglomerate Fosun Group plans to channel its research and development efforts into biosimilars and generic chemicals with more than ¥5 billion (US$800 million) of investment in the coming years. Read More

FDA: Interchangeability, other guidances for biosimilars in the works

The much-awaited guidance on interchangeability the FDA promised last year? It's now on the schedule for 2015, along with other biosimilar draft guidances on labeling, statistical approaches for evaluating analytical similarity data and implementation of the Biologic Price Competition and Innovation Act (BPCIA). Read More

China's Phagelux inks deal with Iveria for phage delivery systems

SHANGHAI – China's Phagelux Inc. has made a deal with Delaware-registered Iveria Technologies Inc. to acquire several biodegradable polymer delivery systems for its phage technologies being developed for both human and agricultural uses. Read More

Financings

Avalanche Biotechnologies, Inc., of Menlo Park, Calif., said it filed a registration statement on Form S-1/A with the SEC relating to a proposed public offering of 2 million shares of its common stock. Read More

Stock movers

Read More

Other news to note

Kite Pharma Inc., of Santa Monica, Calif., reported that the European Commission has conferred orphan status on KTE-C19 for the treatment of diffuse large B-cell lymphoma. Kite has filed an investigational new drug application to conduct a phase I/II trial for KTE-C19 with the FDA, which has also granted the candidate orphan status. Read More

In the clinic

Alkermes plc, of Dublin, disclosed top-line results from FORWARD-1, one of a series of supportive clinical studies in the comprehensive FORWARD phase III pivotal program for the opioid modulator ALKS 5461, a once-daily, oral medicine for major depressive disorder (MDD). Read More

Pharma: Other news to note

Leo Pharma A/S, of Ballerup, Denmark, said it submitted a new drug application to the FDA for calcipotriene/betamethasone dipropionate aerosol foam 0.005 percent/0.064 percent for the treatment of psoriasis vulgaris. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 13, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 13, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe